We investigated the clinical and immunohistochemical availability of DU-PAN-2 (sialyl Lewis
c) as a tumor marker for endometrial adenocarcinomas (EMACs) in comparison with that of CA19-9 (sialyl Lewis
a). Serum DU-PAN-2 and CA19-9 values of 17 EMACs were measured using an EIA kit and a RIA kit, respectively. The positive/negative cutoff values for both markers were set at the [mean+2×SD] from the serum values of 19 benign uterine cases as follows; DU-PAN-2, 73.9 U/mL; CA19-9, 37.4 U/mL. Immunohistochemical expressions of DU-PAN-2 and CA19-9 in EMACs were analyzed, applying an indirect immunoperoxidase method. The Lewis blood group type was determined using the hemagglutination test. The serum elevations of DU-PAN-2 and CA19-9 higher than the cutoff values before surgery were noted in 29.4% (5/17) and 23.5% (4/17) of EMACs, respectively. Except for one patient who died of systemic tumor dissemination, the elevated serum values of DU-PAN-2 and CA19-9 declined to the levels lower than the cutoff values after surgery. The relationship between immunohistochemical profiles and serum values was statistically proven to be closer in DU-PAN-2 (r=0.609,
p=0.0094) than in CA19-9 (r=0.326,
p=0.2022). The Lewis negative patients among them were consistently negative for CA19-9 serologically. We believe that DU-PAN-2 could be clinically useful in EMACs as well as immunohistochemically and recommend that this be added into a panel of tumor markers for EMACs.
View full abstract